Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Insmed Inc (IM8N.BE)

Compare

77.00

-2.00

(-2.53%)

As of 8:08:22 AM GMT+1. Market Open.

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. The FDA provided this update

PR Newswire 21 minutes ago

INSM
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks 2 days ago

INSM

DAWN
Insmed Full Year 2024 Earnings: EPS Misses Expectations

Insmed ( NASDAQ:INSM ) Full Year 2024 Results Key Financial Results Revenue: US$363.7m (up 19% from FY 2023). Net loss...

Simply Wall St. 2 days ago

INSM
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Insmed Inc (INSM) reports robust financial performance and outlines strategic initiatives for future growth, despite challenges in market access and cash burn.

GuruFocus.com 3 days ago

INSM
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 3 days ago

INSM
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -14.78% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 days ago

INSM
Insmed: Q4 Earnings Snapshot

The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.15 per share. The biopharmaceutical developing inhaled treatments for patients battling rare lung diseases posted revenue of $104.4 million in the period, beating Street forecasts. Five analysts surveyed by Zacks expected $104.3 million.

Associated Press Finance 4 days ago

INSM
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

PR Newswire 4 days ago

INSM
Will Insmed Incorporated’s (INSM) New Drugs be Able to Peak Sales?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58% (Institutional Shares) in the quarter compared […]

Insider Monkey 4 days ago

INSM

^RUT
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

Zacks 6 days ago

HALO

FOLD

BMRN
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks 6 days ago

INSM
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 10 days ago

INSM
Insmed To Present at March 2025 Investor Conferences

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

PR Newswire 13 days ago

INSM
Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025.

PR Newswire 14 days ago

INSM
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Zacks 16 days ago

INSM

CSTL

HRMY
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

PR Newswire 17 days ago

INSM
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. In its Day 60 communication to Insmed, the FDA granted Priority Review to the NDA and set a target action date o

PR Newswire 18 days ago

INSM
Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

Pharma Voice last month

RGNX

PFE

INSM
The five-year returns have been solid for Insmed (NASDAQ:INSM) shareholders despite underlying losses increasing

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

Simply Wall St. last month

INSM
Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts?

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other best Russell 2000 stocks to invest in according to analysts. The Russell 2000 Index is a widely followed benchmark that […]

Insider Monkey last month

INSM

^RUT

Performance Overview

Return	IM8N.BE	S&P 500
YTD	+16.67%	+2.24%
1-Year	+208.00%	+18.16%
3-Year	+307.41%	+40.21%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Insmed Inc (IM8N.BE)

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Insmed Full Year 2024 Earnings: EPS Misses Expectations

Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say

Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

Insmed: Q4 Earnings Snapshot

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Will Insmed Incorporated’s (INSM) New Drugs be Able to Peak Sales?

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Insmed To Present at March 2025 Investor Conferences

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

The five-year returns have been solid for Insmed (NASDAQ:INSM) shareholders despite underlying losses increasing

Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts?

Performance Overview